Novo Nordisk Kidney Drug Trial Stopped Early After Positive Results

Novo Nordisk trial testing kidney treatment halted early due to positive results. Trial tested semaglutide, active ingredient in diabetes drug Ozempic.

News boosted shares of Novo Nordisk and Eli Lilly, which makes similar drug Mounjaro. Dialysis firm DaVita shares declined on potential competition.

Trial results could have broad implications for treatment of kidney disease and related conditions like diabetes and obesity.

Novo's semaglutide already approved for diabetes and weight loss, trial shows benefits beyond original use.

DaVita believes trial findings may have limited applicability to overall chronic kidney disease population.